Skip to main content
Premium Trial:

Request an Annual Quote

NINDS Eyes Next-Gen Sequencing Needs

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The National Institute of Neurological Disorders and Stroke is considering how next-generation genome sequencing (NGS) will be applied in studies of neurological disorders, and is asking researchers in this area for information about how they plan to use the latest sequencing tools and genomic data in their work.

To find out how researchers aim to use next-gen whole genome sequencing (WGS), and what the needs are for sequencing, data storage, analysis, and annotation services, NINDS has released a new request for information seeking feedback from the extramural research community.

NINDS will use this feedback to inform and complement its efforts to assess the current and future whole genome sequencing needs of researchers studying a wide range of neurologic disease, and conducting basic research into the nervous system, the genetics of the brain, cognition, brain plasticity, neural signaling, learning, memory, motor control, and other areas.

"Since the technologic advancements in NGS have been rapid, the volume and complexity of the information captured through NGS challenges the storage and processing capabilities of many laboratories and institutions," NINDS said in the RFI.

To find out more about how those challenges should be met, NINDS wants researchers in the extramural community to describe what whole genome sequencing services are available at their institutions and which ones are planned, to describe the makeup of their research cohorts that will use whole genome sequencing, and to discuss how they expect WGS to contribute to their research areas.

The institute also wants to find out why researchers are seeking to use WGS instead of whole exome sequencing, what their sample requirements are expected to be, what kind of storage capacity they have at hand, how many samples they expect to sequence in the coming year, and what plans their labs have for handling and storing whole genome sequencing data.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.